Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
202 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 20 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2017, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape. Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 15, 11, 22, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively. Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 8 Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 18 Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment 19 Assessment by Target 19 Assessment by Mechanism of Action 23 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development 31 Akcea Therapeutics Inc 31 Allergan Plc 31 Ardelyx Inc 32 AstraZeneca Plc 32 Betagenon AB 33 Bird Rock Bio Inc 33 Boehringer Ingelheim GmbH 34 Can-Fite BioPharma Ltd 34 Cerenis Therapeutics Holding SA 35 CJ HealthCare Corp 35 Conatus Pharmaceuticals Inc 36 Corcept Therapeutics Inc 36 CymaBay Therapeutics Inc 37 Daewoong Pharmaceutical Co Ltd 37 Dimerix Bioscience Pty Ltd 38 Dr. Falk Pharma GmbH 38 DURECT Corp 39 Enanta Pharmaceuticals Inc 39 Eternygen GmbH 40 Galmed Pharmaceuticals Ltd 40 Gemphire Therapeutics Inc 41 Genfit SA 41 Gilead Sciences Inc 42 Huons Co Ltd 42 Immuron Ltd 43 Kyorin Pharmaceutical Co Ltd 43 Matinas BioPharma Holdings Inc 44 Metacrine Inc 44 Miyarisan Pharmaceutical Company Ltd 45 Nordic Bioscience A/S 45 NovaTarg Therapeutics Inc 46 Ocera Therapeutics Inc 46 Pfizer Inc 47 Renova Therapeutics Inc 47 Sancilio & Company Inc 48 Shenzhen HighTide Biopharmaceutical Ltd 48 TaiwanJ Pharmaceuticals Co Ltd 49 TCM Biotech International Corp 49 Zydus Cadila Healthcare Ltd 50 Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles 51 (leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile 51 (leucine + PDE5 Inhibitor) - Drug Profile 53 AC-261066 - Drug Profile 54 AF-102 - Drug Profile 55 AKCEA-ANGPTL3LRx - Drug Profile 56 Aramchol - Drug Profile 58 ARI-3037MO - Drug Profile 64 AZD-4076 - Drug Profile 66 C-10 - Drug Profile 68 CBM-588 - Drug Profile 70 cenicriviroc mesylate - Drug Profile 72 CER-209 - Drug Profile 80 CJ-14199 - Drug Profile 82 CORT-118335 - Drug Profile 83 dabigatran etexilate mesylate - Drug Profile 84 DMX-300 - Drug Profile 86 Drug to Antagonize MCJ for Gastrointestinal Disorders - Drug Profile 87 DUR-928 - Drug Profile 88 DWP-10292 - Drug Profile 93 EDP-305 - Drug Profile 94 elafibranor - Drug Profile 96 emricasan - Drug Profile 105 FGF-1 Program - Drug Profile 113 FLB-12 - Drug Profile 114 gemcabene calcium - Drug Profile 115 GS-9674 - Drug Profile 120 HTD-1801 - Drug Profile 123 HU-002 - Drug Profile 124 IMM-124E - Drug Profile 125 KBP-089 - Drug Profile 128 KM-2702 - Drug Profile 129 liothyronine sodium - Drug Profile 130 MAT-8800 - Drug Profile 131 MN-002 - Drug Profile 132 naltrexone hydrochloride - Drug Profile 134 Namacizumab - Drug Profile 136 namodenoson - Drug Profile 137 ND-630 - Drug Profile 143 NLM-0100 - Drug Profile 145 norursodeoxycholic acid - Drug Profile 146 O-304 - Drug Profile 147 oltipraz - Drug Profile 149 ornithine phenylacetate - Drug Profile 150 PF-06835919 - Drug Profile 157 RDX-023 - Drug Profile 158 RT-200 - Drug Profile 159 RT-210 - Drug Profile 160 saroglitazar - Drug Profile 161 SC-410 - Drug Profile 164 seladelpar lysine - Drug Profile 165 selonsertib - Drug Profile 169 Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile 172 Small Molecules for Non-Alcoholic Steatohepatitis and Non Alcoholic Fatty Liver Disease - Drug Profile 173 Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 174 Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile 175 Synthetic Peptides for Non Alcoholic Fatty Liver Disease and Non Alcoholic Steatohepatitis - Drug Profile 176 TCM-606F - Drug Profile 177 tipelukast - Drug Profile 178 Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects 183 Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products 184 Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones 185 Featured News & Press Releases 185 Appendix 197 Methodology 197 Coverage 197 Secondary Research 197 Primary Research 197 Expert Panel Validation 197 Contact Us 197 Disclaimer 198
List of Tables
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Akcea Therapeutics Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Allergan Plc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Ardelyx Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bird Rock Bio Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Boehringer Ingelheim GmbH, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by CJ HealthCare Corp, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by CymaBay Therapeutics Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corp, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Enanta Pharmaceuticals Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gemphire Therapeutics Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Genfit SA, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co Ltd, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Immuron Ltd, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Matinas BioPharma Holdings Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Metacrine Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Nordic Bioscience A/S, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovaTarg Therapeutics Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Ocera Therapeutics Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Pfizer Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Renova Therapeutics Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sancilio & Company Inc, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Ltd, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H2 2017 Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
